Index

Note: Page numbers of article titles are in boldface type.

A

Alpha-hemolysin, 162
AltaStaph, 159
Aminoglycoside(s), for *S. aureus* infections, 112–113
Antibiotic(s), for staphylococcal infections, cycle of use and resistance, 5
Antibody(ies), in blocking *S. aureus* virulence, 163
Antimicrobial resistance, in coagulase-negative staphylococci, 88
Antistaphylococcal agents, 99–131
  aminoglycosides, 112–113
carbapenems, 102
cephalosporins, 101–102
clindamycin, 118–119
daptomycin, 105–107
described, 99–100
doxycycline, 111–112
fluoroquinolones, 113–115
glycylcyclines, 111–112
ß-lactam(s), 100–102
ß-lactam–ß-lactamase inhibitor combinations, 101
linezolid, 107–109
macrolides, 116–117
minocycline, 111–112
monobactams, 102
penicillins, 100–101
rifampin, 115–116
telithromycin, 119
tetracyclines, 111–112
tigecycline, 112
TMP-SMX, 109–110
vancomycin, 102–105
Apoptosis, neutrophil, in *S. aureus* infections, inflammation resolution due to, 22–24
Arginine catabolic mobile element, in *S. aureus* infections, 27
Aurograb, 160

B

Bathing, preoperative, in staphylococcal surgical site infection prevention, 63

C

Carbapenem(s), for *S. aureus* infections, 102
Cardiac devices, infections associated with, coagulase-negative, 76
Central nervous system (CNS) shunt infections, coagulase-negative, 77
Cephalosporin(s), for \textit{S. aureus} infections, 101–102
Cerebrospinal fluid (CSF) shunt infections, coagulase-negative, management of, 85
Clindamycin, for \textit{S. aureus} infections, 118–119
CNS. See Central nervous system (CNS).
Coagulase-negative staphylococcal infections, 73–98. See also \textit{Staphylococcal infections, coagulase-negative}.
Coagulase-negative staphylococci. See \textit{Staphylococcus(i), coagulase-negative}.
Community-associated methicillin-resistant \textit{S. aureus} infections. See \textit{Staphylococcus spp., S. aureus, community-associated methicillin-resistant}.
Community-associated \textit{S. aureus} infections, 35–52. See also \textit{Staphylococcus spp., S. aureus}.
\hspace{1em} defined, 35–37
\hspace{1em} described, 17–18
CSF. See \textit{Cerebrospinal fluid (CSF)}.

\section*{D}
Daptomycin, for \textit{S. aureus} infections, 105–107
Degranulation, neutrophil antimicrobial peptides and proteins and, in \textit{S. aureus} infections, 22
Dialysis, decolonization of \textit{S. aureus} in patients on, 140–143
Doxycycline, for \textit{S. aureus} infections, 111–112

\section*{E}
Empyema, pneumonia with, \textit{S. aureus} and, 42–43
Endocarditis
\hspace{1em} coagulase-negative, 75–76
\hspace{1em} \textit{S. aureus} and, 43–44
Exotoxin vaccines, 162–163

\section*{F}
Fluoroquinolone(s), for \textit{S. aureus} infections, 113–115

\section*{G}
Gene expression, in community-associated methicillin-resistant \textit{S. aureus}, 28
Gene regulation, in community-associated methicillin-resistant \textit{S. aureus}, 28
Glycylcycline(s), for \textit{S. aureus} infections, 111–112

\section*{H}
\textit{\textalpha{}}-Hemolysin, in \textit{S. aureus} infections, 27
Heteropolymers, 161–162
Hospital-associated \textit{S. aureus}, community-associated methicillin-resistant vs., 25–26

\section*{I}
Immunotherapy(ies), staphylococcal vaccines, 153–171. See also \textit{Staphylococcus spp., S. aureus; Staphylococcus spp., S. aureus, community-associated methicillin-resistant}. 
Infection(s), surgical site, staphylococcal, 53–72. See also *Staphylococcal surgical site infections*.

Inflammation, in *S. aureus* infections, neutrophil apoptosis in reduction of, 22–24

Intravascular catheter infections
- coagulase-negative, 74–75
- prevention of, 81–83
- management of, 84–85

**L**

ß-Lactams, for *S. aureus* infections, 100–102
ß-Lactam–ß-lactamase inhibitor combinations, for *S. aureus* infections, 101
Leukocyte(s), polymorphonuclear, in innate immune response to *S. aureus* infections, 18–21
Linezolid, for *S. aureus* infections, 107–109
Luks/F-PV deletion mutants, isogenic community-associated methicillin-resistant *S. aureus*, lessons learned from, 26–27

**M**

Macrolide(s), for *S. aureus* infections, 116–117
Minocycline, for *S. aureus* infections, 111–112
Monobactam(s), for *S. aureus* infections, 102
Multicomponent *S. aureus* adhesin vaccine, 161
Musculoskeletal infections, *S. aureus* and, 40–42

**N**

Nasal colonization, by *S. aureus*, prevention of, vaccine in, 163–164
Neonate(s)
- coagulase-negative staphylococcal infections in, 77–78
- *S. aureus* in, 44
Neutrophil antimicrobial peptides, degranulation and, in *S. aureus* infections, 22
Neutrophil apoptosis, in *S. aureus* infections, inflammation resolution due to, 22–24
Neutrophil extracellular traps, in *S. aureus* infections, 22
Neutrophil microbicidal activity, in *S. aureus* infections, 22–24
Neutrophil recruitment, in innate immune response to *S. aureus* infections, 18–20
Nicotinamide adenine dinucleotide phosphate oxidase, reactive oxygen species production and, in *S. aureus* infections, 22

**P**

Pagibaximab, 160
Panton-valentine leukocidin, in *S. aureus* infections, 26, 27
Penicillin(s), for *S. aureus* infections, 100–101
Peptide(s)
- neutrophil antimicrobial, degranulation and, in *S. aureus* infections, 22
- phenol soluble modulin-like, in *S. aureus* infections, 27–28
Phagocyte(s), function of, *S. aureus* in inhibition of, 24–25
Phagocytosis, in *S. aureus* infections, 20–21
Phenol soluble modulin-like peptides, in *S. aureus* infections, 27–28
PNAG. See Poly-N-acetylglucosamine (PNAG).

Pneumonia(s), with empyema, *S. aureus* and, 42–43
Polymorphonuclear leukocytes, in innate immune response to *S. aureus* infections, 18–21
Poly-N-acetylglucosamine (PNAG), 160
Preoperative bathing, in staphylococcal surgical site infection prevention, 63
Prosthetic devices, coagulase-negative staphylococcal infections due to, 77
Prosthetic joint infections, coagulase-negative, 76–77
management of, 85
Protein(s), neutrophil antimicrobial, degranulation and, in *S. aureus* infections, 22

R

Reactive oxygen species, production of, nicotinamide adenine dinucleotide phosphate oxidase and, in *S. aureus* infections, 22
Rifampin, for *S. aureus* infections, 115–116

S

*S. aureus* clumping factor A-based products, 158–159
Sepsis, severe, *S. aureus* and, 43
Shunt infections
CNS, coagulase-negative, 77
CSF, coagulase-negative, management of, 85
Skin infections
recurrent, prevention of, decolonization of *S. aureus* in, 143
*S. aureus* and, 39–40
Soft tissue infections
recurrent, prevention of, decolonization of *S. aureus* in, 143
*S. aureus* and, 39–40
StaphVAX, 154–157
Staphylococcal infections
coagulase-negative, 73–98
cardiac devices and, 76
cardiac microbiology and molecular typing in, 79–81
cardiac syndromes, 74
CNS shunt infections, 77
CSF shunt infections, 85
device-related, prevention of, 83
endocarditis, 75–76
epidemiology of, 74
in neonates, 77–78
intravascular catheter–related, 74–75
management of, 84–85
prevention of, 81–83
management of, 83–87
pathogenesis of, 79
prevention of, 81
prosthetic devices–related, 77
management of, 85–87
prosthetic joint infections, 76–77, 85
surgical site infections, 77
vascular graft infection, 75
virulence traits in, 79
current status of, 7–8
historical perspective on, 1–15
antibiotics for, cycle of use and resistance, 5
bacterial interference, 3–4
from hospital to community, 6–7
nursery epidemics, new cycle of, 4–5
outbreaks, importance of hand to transmission in, 1–3
surgical site, 53–72. See also *Staphylococcal surgical site infections.*

Staphylococcal surgical site infections, 53–72
burden of inoculation in, 57
coagulase-negative, 77
decrease in, quality improvement programs and process measures in, 62
diagnosis of, 55–56
endogenous contamination in, 57
epidemiology of, 53–54
exogenous contamination in, 57
outcomes of, 54–55
pathogenesis of, 56–58
prevention of, 61–62
controversies in, *S. aureus*–related, 62–64
preoperative bathing in, 63
risk factors for, 58–60
treatment of, 64–65

Staphylococcal vaccines and immunotherapies, 153–171. See also *Staphylococcus spp.*, *S. aureus*, vaccines for.

*Staphylococcus* (i), coagulase-negative
antimicrobial resistance in, 88
described, 73
infections caused by, management of, 83–87
species of, 78–79

*Staphylococcus* spp.
coagulase-negative
*S. haemolyticus*, 79
*S. lugdunensis*, 78–79
*S. saprophyticus*, 78
*S. aureus*
as community pathogen, 35–52
carriage of, decolonization of, in staphylococcal surgical site infection prevention, 63
clinical manifestations of, 39–44
endocarditis, 43–44
musculoskeletal infections, 40–42
pneumonia with empyema, 42–43
severe sepsis, 43
skin and soft tissue infections, 39–40
community-associated
defined, 35–37
described, 17–18
community-associated methicillin-resistant
clinical manifestations of, 39–44
endocarditis, 43–44
in neonates, 44
Staphylococcus spp. (continued)

musculoskeletal infections, 40–42
pneumonia with empyema, 42–43
severe sepsis, 43
skin and soft tissue infections, 39–40
defined, 35–37
in neonates, 44
pathogenesis of, gene expression and regulation in, 28
risk factors for, 37–39
scope of, 37
toxin-producing, infection due to, management issues, 28
transmission of, 37–39
virulence of, 25–26
decolonization of
as infection control measure, 143–144
as prevention strategy, 133–151
for recurrent skin and soft tissue infections, 143
in nonsurgical patients, 139–140
as surgical prophylaxis, 137–139
future research needs related to, 144–145
in dialysis patients, 140–143
rationale for, 133–134
described, 35
epidemiology of, 35–39
hospital-associated, vs. community-associated methicillin-resistant, 25–26
immunotherapies for, 153–171
methicillin-resistant, epidemiology of, 35–39
nasal, eradication of, 134–137
risk factors for, 37–39
surgical site infections due to, 53–54
prevention of, controversies in, 62–64
transmission of, 37–39
treatment of, 99–131. See also Antistaphylococcal agents.
vaccines for, 153–171
active immunization approaches in clinical trials, 154–158
StaphVAX, 154–157
vaccine V710 (IsdB), 157–158
alpha-hemolysin, 162
exotoxin, 162–163
feasibility of, 154
for blocking S. aureus virulence, 163
in nasal colonization prevention, 163–164
in preclinical development, 160–162
heteropolymers, 161–162
multicomponent S. aureus adhesin vaccine, 161
PNAG, 160
passive immunization approaches in clinical trials, 158–160
AltaStaph, 159
Aurograb, 160
pagibaximab, 160
S. aureus clumping factor A-based products, 158–159
superantigens, 163
  target population for, 154
virulence factors of, 58
S. aureus immune evasion, 24–25

S. aureus infections
  arginine catabolic mobile element in, 27
  chemotaxis in, 18–20
  community-associated, described, 17–18
  degranulation and neutrophil antimicrobial peptides and proteins in, 22
described, 17
host defense in, 17–34
innate immune response to, polymorphonuclear leukocytes in, 18–21
neutrophil apoptosis in, inflammation resolution due to, 22–24
neutrophil extracellular traps and, 22
neutrophil microbicidal activity in, 22–24
neutrophil recruitment in, 18–20
nicotinamide adenine dinucleotide phosphate oxidase in, reactive oxygen species production and, 22
pathogen recognition in, 20–21
pathogenesis of, 17–34
phagocytosis in, 20–21
phenol soluble modulin-like peptides in, 27–28
  priming in, 18–20
scope of, 37
α-toxin in, 27
virulence factors in, 26–28

Superantigens, 163

Surgical site infections
  defining of, criteria for, 56
  S. aureus and, prevention of, controversies in, 62–64
  staphylococcal, 53–72. See also Staphylococcal surgical site infections.

T

Telithromycin, for S. aureus infections, 119
Tetracycline(s), for S. aureus infections, 111–112
Tigecycline, for S. aureus infections, 112
TMP-SMX. See Trimethoprim-sulfamethoxazole (TMP-SMX).
α-Toxin, in S. aureus infections, 27
Trimethoprim-sulfamethoxazole (TMP-SMX), for S. aureus infections, 109–110

V

Vaccine(s)
  exotoxin, 162–163
  staphylococcal vaccines, 153–171. See also Staphylococcus spp., S. aureus, vaccines for.
Vaccine V710 (lsdB), 157–158
Vancomycin
  for S. aureus infections, 102–105
  in staphylococcal surgical site infection prevention, 64
Vascular graft infection, coagulase-negative, 75